Chair, Chief Executive, Amgen Inc.
Bradway joined biotech giant Amgen in 2006, becoming chief executive in 2012 and chair a year later. The company has a market cap of nearly $130 billion – making it the second largest public company in the Los Angeles area. In October, Amgen completed its $27.8 billion acquisition of Dublin, Ireland-based Horizon Therapeutics, overcoming federal government opposition to the deal. Amgen then moved to incorporate Horizon’s drug development program into a new business line for therapeutics for rare diseases. In the years leading up to the acquisition, Bradway honed Amgen’s focus on drugs to treat cancers as well as cardiovascular and inflammatory diseases. Prior to joining Amgen, Bradway spent 20 years at Morgan Stanley, rising through the ranks to become managing director at the finance firm’s London office. Bradway is also a director of Boeing Co. and chairs its finance committee.
YEARS ON LA500: 9
